Patents by Inventor Jeffrey A. Moscow

Jeffrey A. Moscow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microcystins as agents for treatment of cancer
    Patent number: 9006173
    Abstract: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 14, 2015
    Assignee: University of Kentucky Research Foundation
    Inventors: Noel R. Monks, Shuqian Liu, Jeffrey A. Moscow
  • Compositions and methods for selectively targeting cancer cells using a thiaminase compound
    Patent number: 8663632
    Abstract: Compositions and methods of treating cancer using a thiaminase compound are described. The presently-disclosed subject matter includes a method of treating cancer by administering a thiaminase compound and a thiamine-dependent enzyme inhibitor.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: March 4, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Jeffrey Moscow, Shuqian Liu, Younsoo Bae
  • Organic cation transporter preferentially expressed in hematopoietic cells and leukemias and uses thereof
    Patent number: 7723019
    Abstract: A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: May 25, 2010
    Assignee: University of Kentucky Research Foundation
    Inventors: Jeffrey Moscow, Xin Lu, Craig Jordan
  • Microcystins as agents for treatment of cancer
    Publication number: 20070275885
    Abstract: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.
    Type: Application
    Filed: May 10, 2007
    Publication date: November 29, 2007
    Applicant: UNIVERSITY OF KENTUCKY
    Inventors: Noel Monk, Shuqian Liu, Jeffrey Moscow
  • Organic cation transporter preferentially expressed in hematopoietic cells and leukemias and uses thereof
    Publication number: 20070269846
    Abstract: A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.
    Type: Application
    Filed: September 15, 2006
    Publication date: November 22, 2007
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Jeffrey Moscow, Xin Lu, Craig Jordan
  • Gene encoding a human reduced folate carrier (RFC)
    Patent number: 5763216
    Abstract: One shortcoming of methotrexate chemotherapy is that previously responsive tumors can become refractory to methotrexate after continued exposure. Such methotrexate resistance may be due to underexpression of reduced folate carrier (RFC) protein. The present invention provides DNA molecules encoding human RFC. The present invention also relates to expression vectors comprising RFC-encoding DNA molecules, and to the use of such vectors to restore methotrexate sensitivity in mammalian cells. The present invention further relates to antibodies that bind with human RFC protein, and to methods of detecting human RFC protein using such antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Jeffrey A. Moscow, Kenneth H. Cowan, Kathy Dixon, Rui He
  • Antibodies to human reduced folate carrier protein
    Patent number: 5716788
    Abstract: One shortcoming of methotrexate chemotherapy is that previously responsive tumors can become refractory to methotrexate after continued exposure. Such methotrexate resistance may be due to underexpression of reduced folate carrier (RFC) protein. The present invention provides DNA molecules encoding human RFC. The present invention also relates to expression vectors comprising RFC-encoding DNA molecules, and to the use of such vectors to restore methotrexate sensitivity in mammalian cells. The present invention further relates to antibodies that bind with human RFC protein, and to methods of detecting human RFC protein using such antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey A. Moscow, Kenneth H. Cowan, Kathy Dixon, Rui He